Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.71 |
| ▸ | NPC1 | O15118 | 2/20 | 0.71 |
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | TP53 | P04637 | 2/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.63 |
| ▸ | AR | P10275 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | PPARG | P37231 | 3/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22729259 | 0.85 | MAPT (0.81) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| Chrysin Dimethyl Ether SCHEMBL29403280 | 0.83 | ABCG2 (1.00) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| Chrysin Dimethyl Ether SCHEMBL1676012 | 0.83 | ABCG2 (1.00) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| SCHEMBL30376090 | 0.79 | L3MBTL1 (0.77) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| SCHEMBL19267888 | 0.79 | L3MBTL1 (0.77) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| SCHEMBL1629391 | 0.77 | ALDH1A1 (1.00) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| SCHEMBL4051739 | 0.77 | KDM4E (0.78) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| SCHEMBL20100898 | 0.77 | KDM4E (0.78) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| Chrysin Diacetate SCHEMBL15263635 | 0.76 | KDM4E (0.78) | KDM4EALDH1A1ABCG2NPC1MEN1 | |
| SCHEMBL11657461 | 0.76 | KDM4E (0.75) | KDM4EALDH1A1ABCG2NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | claimed |
| US-20210038562-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | FRONTBIO INC. (KR) | 2021-02-11 | — | — | US | claimed |
| EP-3747435-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | FRONTBIO INC. (KR) | 2020-12-09 | — | — | EP | claimed |
| CN-111655254-A | Pharmaceutical composition for preventing or treating diabetic complications comprising novel chrysin derivative compounds as active ingredients | 先生株式会社 | 2020-09-11 | — | — | CN | claimed |
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | MEDIENCE CO., LTD. (KR) | 2023-04-20 | — | — | US | disclosed |
| US-20210038562-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | FRONTBIO INC. (KR) | 2021-02-11 | — | — | US | disclosed |
| EP-3747435-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | FRONTBIO INC. (KR) | 2020-12-09 | — | — | EP | disclosed |
| CN-111655254-A | Pharmaceutical composition for preventing or treating diabetic complications comprising novel chrysin derivative compounds as active ingredients | 先生株式会社 | 2020-09-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119060-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE | SLC5A2, SLC5A1, SLC5A6 | KDM4E 1490/4885ALDH1A1 2243/4885ABCG2 15/4885 |
| US-20210038562-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES COMPLICATIONS COMPRISING NOVEL CHRYSIN DERIVATIVE COMPOUND AS ACTIVE INGREDIENT | AGER, IAPP, GCG | KDM4E 3001/4885ALDH1A1 3474/4885ABCG2 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.